DDInter534 DDInter1094
A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of gamma-aminobutyric acid activity. It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome. (From Martindale, The Extra Pharmacopoeia, 30th ed, p589) Given diazepam's storied history as a commonly used and effective medication for a variety of indications, contemporary advancements in the formulation and administration of the agent include the development and US FDA approval of an auto-injectable formulation for the rapid treatment of uncontrolled seizures in 2015-2016. Combining diazepam, a proven effective therapy for acute repetitive seizures
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Diazepam {u} (Compound) resembles {v} (Compound) Oxazepam
Oxazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Diazepam {u} (Compound) resembles {v} (Compound) Lorazepam
Lorazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Diazepam {u} (Compound) resembles {v} (Compound) Oxazepam
Oxazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Diazepam {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Diazepam {u} (Compound) resembles {v} (Compound) Temazepam
Temazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Diazepam {u} (Compound) resembles {v} (Compound) Lorazepam
Lorazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Diazepam {u} (Compound) resembles {v} (Compound) Quazepam
Quazepam {u} (Compound) resembles {v} (Compound) Flurazepam
Flurazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Diazepam {u} (Compound) resembles {v} (Compound) Oxazepam
Oxazepam {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Diazepam {u} (Compound) resembles {v} (Compound) Temazepam
Temazepam {u} (Compound) resembles {v} (Compound) Oxazepam
Oxazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Diazepam {u} (Compound) resembles {v} (Compound) Quazepam
Quazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Diazepam (Compound) resembles Oxazepam (Compound) and Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Diazepam (Compound) resembles Lorazepam (Compound) and Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Diazepam (Compound) resembles Oxazepam (Compound) and Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Diazepam (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Diazepam (Compound) resembles Temazepam (Compound) and Temazepam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Diazepam (Compound) resembles Lorazepam (Compound) and Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Diazepam (Compound) resembles Quazepam (Compound) and Quazepam (Compound) resembles Flurazepam (Compound) and Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Diazepam (Compound) resembles Oxazepam (Compound) and Oxazepam (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Diazepam (Compound) resembles Temazepam (Compound) and Temazepam (Compound) resembles Oxazepam (Compound) and Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Diazepam (Compound) resembles Quazepam (Compound) and Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib